Threshold Pharmaceuticals Inc., of Redwood City, Calif., said the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio started a 28-patient trial of TH-302 in combination with Avastin (bevacizumab, Roche AG) in patients with recurrent high-grade astrocytoma, including glioblastoma. The study will enroll patients whose disease has progressed following both combined modality treatment with radiation and temozolomide chemotherapy, as well as therapy with Avastin.